ENTA · CIK 0001177648 · operating
Enanta Pharmaceuticals is a biotechnology company focused on discovering and developing small molecule drugs targeting virology and immunology indications. The company's pipeline includes multiple candidates in clinical development: EDP-514 for chronic hepatitis B infection (Phase 1b), zelicapavir and EDP-323 for respiratory syncytial virus (Phase II), EDP-235 for human coronaviruses (Phase II), EDP-978 for chronic spontaneous urticaria, and EPS-3903 for atopic dermatitis. The company also markets glecaprevir, an HCV protease inhibitor developed under a collaborative agreement with Abbott Laboratories.
Revenue generation is supported through a collaborative development and license agreement with Abbott for hepatitis C viral protease inhibitor compounds, including paritaprevir and glecaprevir. This partnership provides a revenue stream while the company advances its earlier-stage pipeline candidates through clinical development.
Enanta operates with approximately 120 full-time employees and is headquartered in Watertown, Massachusetts. The company was incorporated in 1995 and trades on the Nasdaq. Its operations are primarily based in the United States.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-3.84 | $-3.84 | +29.9% | |
| 2024 | $-5.48 | $-5.48 | +14.1% | |
| 2023 | $-6.38 | $-6.38 | -8.0% | |
| 2022 | $-5.91 | $-5.91 | -50.8% | |
| 2021 | $-3.92 | $-3.92 | -168.5% | |
| 2020 | $-1.46 | $-1.46 | -431.8% | |
| 2019 | $0.44 | $0.47 | -66.2% | |
| 2018 | $1.30 | $1.41 | -30.1% | |
| 2017 | $1.86 | $1.91 | +2166.7% | |
| 2016 | $-0.09 | $-0.09 | -131.0% | |
| 2015 | $0.29 | $0.30 | +207.4% | |
| 2014 | $-0.27 | $-0.27 | -8.0% | |
| 2013 | $-0.25 | $-0.25 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-09-30 | 2025-11-19 | 0001193125-25-288121 | SEC ↗ |
| 2024-09-30 | 2024-11-27 | 0000950170-24-131260 | SEC ↗ |
| 2023-09-30 | 2023-11-22 | 0000950170-23-065884 | SEC ↗ |
| 2022-09-30 | 2022-11-23 | 0000950170-22-025667 | SEC ↗ |
| 2021-09-30 | 2021-11-24 | 0000950170-21-004895 | SEC ↗ |
| 2020-09-30 | 2020-11-25 | 0001564590-20-055233 | SEC ↗ |
| 2019-09-30 | 2019-11-27 | 0001564590-19-044729 | SEC ↗ |
| 2018-09-30 | 2018-11-29 | 0001564590-18-030275 | SEC ↗ |
| 2017-09-30 | 2017-12-11 | 0001564590-17-024794 | SEC ↗ |
| 2016-09-30 | 2016-12-09 | 0001193125-16-789660 | SEC ↗ |
| 2015-09-30 | 2015-12-11 | 0001193125-15-401602 | SEC ↗ |
| 2014-09-30 | 2014-12-11 | 0001193125-14-440235 | SEC ↗ |
| 2013-09-30 | 2013-12-18 | 0001193125-13-477878 | SEC ↗ |